REG - BioPharma Credit PLC - Transaction in Own Shares

Biopharma CreditAnnouncement

10/07/2023 18:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230710:nRSJ5540Fa&default-theme=true

RNS Number : 5540F  BioPharma Credit PLC  10 July 2023

BioPharma Credit plc

(the "Company")

TRANSACTION IN OWN SHARES

 

BioPharma Credit PLC (the "Company") announces that today it has purchased the
following number of its ordinary shares of US$0.01 each on the London Stock
Exchange through J.P. Morgan Securities plc into treasury.

 

Ordinary Shares: BPCR LN

Date of purchase: 10 July 2023

Number of ordinary shares purchased: 1,260,909

Lowest price per share: $0.8820

Highest price per share: $0.8860

Trading venue: London Stock Exchange

Aggregate volume per date per trading venue: 1,260,909

Weighted average price per day per trading venue: $0.8820

 

Following the above transaction, the Company holds 70,552,875 of its ordinary
shares in treasury and has 1,303,379,192 ordinary shares in issue (excluding
treasury shares). Therefore, the total number of voting rights in the Company
is 1,303,379,192. This figure may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the Company under
the FCA's Disclosure Guidance and Transparency Rules.

 

 

 

Enquiries:

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

+44 (0)1392 477 500

 

Buchanan

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

+44 (0)20 7466 5000

biopharmacredit@buchanan.uk.com (mailto:biopharmacredit@buchanan.uk.com)

 

Notes to Editors:

 

BioPharma Credit PLC is London's only listed specialist investor in debt from
the life sciences industry and joined the LSE on 27 March 2017. The Company
seeks to provide long-term shareholder returns, principally in the form of
sustainable income distributions from exposure to the life sciences industry.
The Company seeks to achieve this objective primarily through investments in
debt assets secured by royalties or other cash flows derived from the sales of
approved life sciences products.

 

 

 

LEI: 213800AV55PYXAS7SY24

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSQBLFFXDLFBBX